Results 1 to 10 of about 362 (162)

Clinical Outcomes of MLC601 (NeuroAiD^TM) in Traumatic Brain Injury: A Pilot Study [PDF]

Brain Sciences, 2020
Background: MLC601 is a natural product formulation from Chinese medicine that is extensively studied in ischemic stroke. Traumatic brain injury (TBI) shares pathophysiological mechanisms with ischemic stroke, yet there are few studies on the use of ...
Asra Al Fauzi, Krisna Tsaniadi Prihastomo, I. G. M. Aswin R. Ranuh, Tedy Apriawan, Joni Wahyuhadi, M. Arifin Parenrengi, Agus Turchan, Abdul Hafid Bajamal, Hari Basuki Notobroto   +8 more
doaj   +6 more sources

NeuroAid II (MLC901) in Haemorrhagic Stroke [PDF]

Case Reports in Neurology, 2020
Stroke is a leading cause of death and disability. NeuroAid (MLC601), which originates from Traditional Chinese Medicine, comprises herbal and animal components, and has been shown to improve the functional status of patients after ischaemic stroke.
Chai-Hoon Nowel Tan, David Choy, Narayanaswamy Venketasubramanian   +2 more
doaj   +5 more sources

Antiepileptic Effect of Neuroaid^® on Strychnine-Induced Convulsions in Mice [PDF]

Pharmaceuticals, 2022
NeuroAid II, a folk Chinese Medicine, is currently used in Asia for the treatment of stroke. An experimental study demonstrated that NeuroAid enables neuronal cells to be more resistant to glutamate toxicity. This research was constructed to evaluate the
Ahmed Salim Mahmood, Afaq M. Ammoo, Mayssam Hussein Mohammed Ali, Tiba M. Hameed, Hany A. Al-Hussaniy, Abdulla Amer Abbas Aljumaili, Mohammed Hussein Alaa Al-Fallooji, Ali Hakim Kadhim   +7 more
doaj   +2 more sources

Effects of morphine and NeuroAid on the expression levels of GluN2A and GluN3A in the hippocampus and striatum of rats [PDF]

Iranian Journal of Basic Medical Sciences, 2021
Objective(s): NMDA glutamatergic receptors are heteromeric receptors with various subunits. GluN2A and GluN3A subunits specify the functional heterogeneity of NMDA receptors. These subunits play a key role in the induction of LTP and synaptic plasticity.
Katayoun Heshmatzad, Mohammad Nasehi, Salar Vaseghi   +2 more
doaj   +2 more sources

Ischemic Stroke and Savings in Time to Achieve Functional Recovery: Experience from NeuroAiD [PDF]

Journal of Cardiovascular Development and Disease, 2023
Despite recent progress with revascularisation interventions after acute ischemic stroke, many patients remain disabled after stroke. Using data from a multi-centre, randomised, double-blind, placebo-controlled trial of a neuro-repair treatment (NeuroAiD/
Narayanaswamy Venketasubramanian, Yogesh Pokharkar, Jia Hui Chai, Christopher Li Hsian Chen   +3 more
doaj   +2 more sources

Safety and Use of MLC601/MLC901 (NeuroAiD^TM) in Primary Intracerebral Hemorrhage: A Cohort Study from the NeuroAiD Safe Treatment Registry [PDF]

Brain Sciences, 2020
Background: MLC601/MLC901 (NeuroAiD™) is a combination of natural products shown to be safe and to aid neurological recovery after brain injuries, especially ischemic stroke. Few studies have investigated NeuroAiD in primary intracerebral hemorrhage (ICH)
Ramesh Kumar, Azizi Abu Bakar, Jegan Thanabalan, Sanmugarajah Paramasvaran, Charng Jeng Toh, Ainul Jaffar, Farizal Fadzil, Palaniandy Kamalanathan, Bee Hong Soon, Narayanaswamy Venketasubramanian   +9 more
doaj   +2 more sources

Beyond stroke therapy, neuroaid (a chinese herbal) has an effect on cognition and neurogenesis, a bibliometric study [version 2; peer review: 2 approved] [PDF]

F1000Research
Introduction NeuroAiD, also known as MLC601 or MLC901, is a Chinese herbal combination used worldwide for stroke treatment. It contains herbal components and five hewan components.
Dwi Arwandi Yogi Saputra, Tirta Darmawan Susanto, ARMAN YURISALDI SALEH, Riezky Valentina   +3 more
doaj   +2 more sources

Randomised, double-blind, placebo-controlled study investigating Safety and efficAcy of MLC901 in post-traUmatic bRAin Injury: the SAMURAI study protocol [PDF]

BMJ Open, 2022
Introduction Traumatic brain injury (TBI) is a leading cause of death in young adults globally and 90% of cases are mild TBI. Treatment to facilitate recovery after TBI is needed.
Marek Majdan, Valery Feigin, Pavel Pilipenko, Anna Andreevna Ivanova, Yulia Vadimovna Kotsiubinskaya, Vera Naumovna Grigoryeva, Alexey Yevgenievich Khrulev   +6 more
doaj   +2 more sources

Integrative molecular simulations reveal NeuroAid II mechanisms in ischemic stroke through network pharmacology, molecular dynamics, and pharmacophore modeling [PDF]

Scientific Reports
Ischemic stroke remains a major health challenge with limited treatment options. NeuroAid II (MLC901), a multi-herbal remedy, has shown clinical promise in post-stroke recovery, though its molecular mechanisms are unclear.
Doni Dermawan, Stefeny Theresia Simatupang, Nadia Nadia, Santi Tan, Raymond Rubianto Tjandrawinata   +4 more
doaj   +2 more sources

Systematic Review and Meta-Analysis of the Efficacy of MLC901 (NeuroAiD II) for Acute Ischemic Brain Injury in Animal Models [PDF]

Journal of Evidence-Based Integrative Medicine, 2021
Introduction. Moleac (MLC) 901 is a traditional Chinese medication approved by the Sino Food and Drug Administration in 2001 for treating stroke. This study aims to analyze the efficacy of MLC901 in animal stroke models after medial cerebral artery ...
I. G. M. Aswin R. Ranuh MD, Gadis Meinar Sari MD, PhD, Budi Utomo MD, PhD, Nur Setiawan Suroto MD, Asra Al Fauzi MD, PhD   +4 more
doaj   +2 more sources